| Date:                         | 1/7/2022   |
|-------------------------------|--|
| Your Name:                    | Song Yang ]  |
| Manuscript Title:             | [Relationship between Carotid artery stiffness and total serum homocysteine in the coronary slow flow phenomenon: A high- resolution echo-tracking study ] |
| Manuscript Number (if known): | QIMS-21-931-R3   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
|   |   | Time frame: Since the initial planning  | of the work   |
|   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month   | s   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None  |   |
| 3 | Royalties or licenses   | None  |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |   |
| 6  | Payment for expert testimony   | [⊠] None   |   |
| 7  | Support for attending meetings and/or travel   | [⊠ None  |   |
| 8  | Patents planned,<br>issued or<br>pending   | [⊠] None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | [⊠] None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock options  | [⊠] None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | [⊠] None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | [⊠] None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 1/10/2022  |
|-------------------------------|--|
| Your Name:                    | Wen He   |
| Manuscript Title:             | [Relationship between Carotid artery stiffness and total serum homocysteine in the coronary slow flow phenomenon: A high- resolution echo-tracking study |
| Manuscript Number (if known): | QIMS-21-931-R3   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|  |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--|---|--|---|
| 1 All support for the present manuscript (e.g.,                      |   | Time frame: Since the initial planning $[oxtimes]$ None                                      | of the work   |
| funding,<br>of study<br>medical<br>article pi<br>charges,<br>No time | funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. |  | Click the tab key to add additional rows.   |
|  |   | Time frame: past 36 month  | ns  |
| 2  | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).                                    | [⊠] None   |   |
| 3  | Royalties or<br>licenses  | None None  |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |   |
| 6  | Payment for expert testimony   | [⊠] None   |   |
| 7  | Support for attending meetings and/or travel   | [⊠ None  |   |
| 8  | Patents planned,<br>issued or<br>pending   | [⊠] None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | [⊠] None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock options  | [⊠] None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | [⊠] None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | [⊠] None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 1/12/2022  |
|-------------------------------|--|
| Your Name:                    | _Yi Li ]   |
| Manuscript Title:             | [Relationship between Carotid artery stiffness and total serum homocysteine in the coronary slow flow phenomenon: A high- resolution echo-tracking study |
| Manuscript Number (if known): | QIMS-21-931-R3   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|  |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--|---|--|---|
| 1 All support for the present manuscript (e.g.,                      |   | Time frame: Since the initial planning $[oxtimes]$ None                                      | of the work   |
| funding,<br>of study<br>medical<br>article pi<br>charges,<br>No time | funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. |  | Click the tab key to add additional rows.   |
|  |   | Time frame: past 36 month  | ns  |
| 2  | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).                                    | [⊠] None   |   |
| 3  | Royalties or<br>licenses  | None None  |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |   |
| 6  | Payment for expert testimony   | [⊠] None   |   |
| 7  | Support for attending meetings and/or travel   | [⊠ None  |   |
| 8  | Patents planned,<br>issued or<br>pending   | [⊠] None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | [⊠] None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock options  | [⊠] None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | [⊠] None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | [⊠] None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 1/13/2022  |
|-------------------------------|--|
| Your Name:                    | Fumin Wang   |
| Manuscript Title:             | [Relationship between Carotid artery stiffness and total serum homocysteine in the coronary slow flow phenomenon: A high- resolution echo-tracking study ] |
| Manuscript Number (if known): | QIMS-21-931-R3   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 All support for the present   |   | Time frame: Since the initial planning $[oxtimes]$ None                                      | of the work   |
| of study ma<br>medical wr<br>article prod<br>charges, et<br>No time lin | funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. |  | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | ns  |
| 2   | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).                                    | [⊠] None   |   |
| 3   | Royalties or<br>licenses  | None None  |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |   |
| 6  | Payment for expert testimony   | [⊠] None   |   |
| 7  | Support for attending meetings and/or travel   | [⊠ None  |   |
| 8  | Patents planned,<br>issued or<br>pending   | [⊠] None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | [⊠] None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None   |   |

|        |  | Name all entities with whom you have this relationship or indicate none (add rows as need | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--------|--|---|---|
| 11     | Stock or stock<br>options  | None  |   |
| 12     | Receipt of equipment, materials, drugs, medical writing, gifts or other services | [⊠] None  |   |
| 13     | Other financial or<br>non-financial<br>interests                                 | [⊠] None  |   |
| Plea 🖂 | Please place an "X" next to the following statement to indicate your agreement:  |   |   |

3 12/13/2021 ICMJE Disclosure Form

| Date:                         | 1/13/2022  |
|-------------------------------|--|
| Your Name:                    | [Lu Yin ]  |
| Manuscript Title:             | [Relationship between Carotid artery stiffness and total serum homocysteine in the coronary slow flow phenomenon: A high- resolution echo-tracking study ] |
| Manuscript Number (if known): | QIMS-21-931-R3   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   |  | ons/Comments (e.g., if payments were u or to your institution) |
|---|---|--|--|
|   |   | Time frame: Since the initial planning of the work |  |
|   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Click the tab ke                             | y to add additional rows.                                      |
|   |   | Time frame: past 36 months                         |  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | [⊠] None   |  |
| 3 | Royalties or<br>licenses  | None   |  |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |   |
| 6  | Payment for expert testimony  | [⊠] None   |   |
| 7  | Support for attending meetings and/or travel  | [⊠] None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | [⊠] None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | [⊠] None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | [⊠] None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock options  | [⊠] None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | [⊠] None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | [⊠] None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 1/13/2022  |
|-------------------------------|--|
| Your Name:                    | _[Ll juan Du ]   |
| Manuscript Title:             | [Relationship between Carotid artery stiffness and total serum homocysteine in the coronary slow flow phenomenon: A high- resolution echo-tracking study |
| Manuscript Number (if known): | QIMS-21-931-R3   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 All support for the present   |   | Time frame: Since the initial planning $[oxtimes]$ None                                      | of the work   |
| of study ma<br>medical wr<br>article prod<br>charges, et<br>No time lin | funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. |  | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | ns  |
| 2   | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).                                    | [⊠] None   |   |
| 3   | Royalties or<br>licenses  | None None  |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |   |
| 6  | Payment for expert testimony   | [⊠] None   |   |
| 7  | Support for attending meetings and/or travel   | [⊠ None  |   |
| 8  | Patents planned,<br>issued or<br>pending   | [⊠] None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | [⊠] None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None   |   |

|      |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|---|
| 11   | Stock or stock options   | [⊠] None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services | [⊠] None   |   |
| 13   | Other financial or<br>non-financial<br>interests                                 | [⊠] None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  |  |   |